EP2646031
Aukið aðgengi lyfja við meðferð með naltrexóni
Status:
EP einkaleyfi í gildi á ÍslandiEP appl. date:
2.12.2011EP published:
22.2.2017EP application number:
11845186.3
EP translation filed:
10.5.2017Grant published:
15.6.2017EPO information:
European Patent Register
Max expiry date:
1.12.2031Expiry date:
1.12.2026Next due date:
31.12.2026
Title:
INCREASING DRUG BIOAVAILABILITY IN NALTREXONE THERAPY
Timeline
Today
2.12.2011EP application
22.2.2017EP Publication
10.5.2017Translation submitted
15.6.2017Registration published
1.12.2026Expires
Owner
Name:
Orexigen Therapeutics, Inc.Address:
3344 North Torrey Pines Court, Suite 200, 92037, La Jolla, CA, US
Inventor
Name:
FLANAGAN, ShawnAddress:
San DiegoCA, US
Name:
DUNAYEVICH, EduardoAddress:
Westlake Village, CA, US
Agent
Name:
Árnason Faktor ehf.Address:
Guðríðarstíg 2-4, 113, Reykjavík,
Priority
Number:
419395 PDate:
3.12.2010Country:
US
Classification
Categories:
A61K 31/485, A61K 31/137, A61P 3/04
Annual fees
Number
Paid
Expires
Payer
Number: 7
Paid: 9.11.2017
Expires: 1.12.2018
Payer: Árnason Faktor
Number: 8
Paid: 6.11.2018
Expires: 1.12.2019
Payer: Árnason Faktor
Number: 9
Paid: 7.11.2019
Expires: 1.12.2020
Payer: Árnason Faktor
Number: 10
Paid: 6.11.2020
Expires: 1.12.2021
Payer: Árnason Faktor ehf.
Number: 11
Paid: 8.11.2021
Expires: 1.12.2022
Payer: Árnason Faktor ehf.
Number: 12
Paid: 30.11.2022
Expires: 1.12.2023
Payer: Árnason Faktor ehf.
Number: 13
Paid: 15.11.2023
Expires: 1.12.2024
Payer: Árnason Faktor ehf.
Number: 14
Paid: 28.11.2024
Expires: 1.12.2025
Payer: Árnason Faktor ehf.
Number: 15
Paid: 5.12.2025
Expires: 1.12.2026
Payer: Árnason Faktor ehf.